Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Saint Priest En Jarez – page 58

1 694 clinical trials in Saint Priest En Jarez, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint Priest En Jarez at a glance
1 694
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 694 trials in Saint Priest En Jarez

Open in trial search

Diabetic retinal oedema

Not yet recruiting

Efficacy and Safety of Intravitreal MK-8748 Compared with Aflibercept in Adults with Diabetic Macular Edema

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Chronic lymphocytic leukaemia+1

Not yet recruiting

Phase II Study of Zanubrutinib in Elderly, Treatment‑Naïve Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Zanubrutinib
  • Sponsor:LYSARC

Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Arthralgia

Not yet recruiting

Efficacy of embolization using ethyl esters of iodised fatty acids and ioversol in patients with painful joints (knee osteoarthritis, frozen shoulder, elbow tendinopathy)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ioversol
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not yet recruiting

Phase III Study of Izalontamab Brengitecan with Drug Combination versus Osimertinib Alone in First‑Line EGFR‑Mutated Advanced or Metastatic Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Colitis ulcerative

Not yet recruiting

Evaluation of Upadacitinib Re‑induction in Patients with Ulcerative Colitis Who Have Lost Response to a 30 mg Maintenance Dose

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:i-GETAID

Retinoblastoma

Not yet recruiting

Carboplatin with drug combination for children with unilateral retinoblastoma undergoing enucleation: study of tumor biomarkers and relapse risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Reducing abemaciclib, palbociclib and ribociclib after complete response in HER2‑negative metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Unicancer

HIV infection

Not yet recruiting

Study of Baricitinib and Sirolimus to Maintain HIV Infection Control After Antiretroviral Treatment Interruption in Adults

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Acute myeloid leukaemia

Not yet recruiting

Study of quizartinib‑based drug combination on measurable residual disease in adults 18‑60 with acute myeloid leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Saint Priest En Jarez

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on head and neck cancer, multiple myeloma, and acute myeloid leukemia. Studies evaluating novel therapeutic approaches including targeted treatments and combination therapies.

  • Head & Neck Squamous Cell Carcinoma
  • Multiple Myeloma Treatment
  • Pancreatic Adenocarcinoma

Investigating breakthrough treatments and improving patient outcomes through innovative therapeutic strategies.

02 Autoimmune Disorders

Comprehensive research into inflammatory conditions and autoimmune diseases, with particular focus on Crohn's disease, rheumatoid arthritis, and novel treatment approaches.

  • Psoriatic Arthritis
  • Ulcerative Colitis
  • Sjögren's Syndrome

Evaluating advanced therapies and treatment combinations to improve disease management and patient quality of life.

03 Cardiovascular & Pulmonary Studies

Innovative research in pulmonary arterial hypertension and related conditions, exploring new therapeutic options and treatment strategies.

  • Pulmonary Hypertension
  • Chronic Kidney Disease
  • Cardiovascular Complications

Testing novel compounds and therapeutic approaches to address complex cardiovascular and pulmonary conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.